Levodopa controlled release - APeT

Drug Profile

Levodopa controlled release - APeT

Alternative Names: ConstaDopa; Levodopa - APeT

Latest Information Update: 04 Jan 2017

Price : $50

At a glance

  • Originator APeT
  • Class Antiparkinsonians; Catecholamines; Small molecules
  • Mechanism of Action Dopamine receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Parkinson's disease

Most Recent Events

  • 04 Jan 2017 Chemical structure information added
  • 13 Dec 2016 Clinical trials in Parkinson's disease in Netherlands (PO) before December 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top